HOSE1 EVs were injected i.p. from day 3 and every other day thereafter, for a total of 6 times. The mice were euthanized on day 30. Lower: Distribution of photon count in the dissected primary tumor (left) and the peritoneal metastatic tumors (right). n = 6; HOSE1 EV, n = 6; ES-2 EV. Student's t-test (*p < 0.05 and NS = no significance). (c) Upper: Schematic protocol for investigating the EVs in peritoneal dissemination. Orthotopic mouse models were established with RMG-1 cells. ES-2 EVs and HOSE1 EVs were injected i.p. from day 21, every other day thereafter, for a total of 6 times. The mice were euthanized on day 42. Lower: Distribution of photon count in the dissected primary tumor (left) and the peritoneal metastatic tumors (right). n = 6; HOSE1 EV, n = 6; ES-2 EV. Student's t-test (*p < 0.05 and NS = no significance).
Supplementary Figure 3.
In vivo experiments determine dose-dependency of the EVs for peritoneal MeT-5A cells after the addition of ES-2 EVs and HOSE1 EVs as described in Fig. 2a The EVs were isolated from 5 mL of ascites, and total RNA was extracted. The amount of total RNA was measured by a bioanalyzer (Agilent) and that of GAPDH by qRT-PCR. Pearson's R value is shown in the graph. (b) Correlation between the amount of proteins and the number of particles in EVs from patients' ascites. Eight patient ascites samples were randomly selected. The EVs were isolated from 5 mL of ascites, and the amount of proteins and the number of particles were measured. Pearson's R value is shown in the graph. The list from the gene set enrichment analysis (GSEA) of the mesothelial cells (Met-5A) treated with 3 cancer EVs versus those with HOSE1 EVs. Four types of comparison were performed, and significantly enriched pathways are listed.
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